INCR vs. CDTX, ACB, TSVT, CRDF, OLMA, DRUG, LFCR, MNPR, ENGN, and FHTX
Should you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Cidara Therapeutics (CDTX), Aurora Cannabis (ACB), 2seventy bio (TSVT), Cardiff Oncology (CRDF), Olema Pharmaceuticals (OLMA), Bright Minds Biosciences (DRUG), Lifecore Biomedical (LFCR), Monopar Therapeutics (MNPR), enGene (ENGN), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry.
InterCure vs.
InterCure (NASDAQ:INCR) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations, valuation and community ranking.
InterCure has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. InterCure's return on equity of 0.00% beat Cidara Therapeutics' return on equity.
In the previous week, Cidara Therapeutics had 1 more articles in the media than InterCure. MarketBeat recorded 3 mentions for Cidara Therapeutics and 2 mentions for InterCure. InterCure's average media sentiment score of 0.93 beat Cidara Therapeutics' score of 0.47 indicating that InterCure is being referred to more favorably in the media.
InterCure has higher revenue and earnings than Cidara Therapeutics.
InterCure has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
8.3% of InterCure shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 0.2% of InterCure shares are held by insiders. Comparatively, 7.6% of Cidara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cidara Therapeutics has a consensus target price of $39.14, suggesting a potential upside of 74.82%. Given Cidara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cidara Therapeutics is more favorable than InterCure.
Cidara Therapeutics received 452 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 70.43% of users gave Cidara Therapeutics an outperform vote.
Summary
Cidara Therapeutics beats InterCure on 9 of the 17 factors compared between the two stocks.
Get InterCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InterCure Competitors List
Related Companies and Tools
This page (NASDAQ:INCR) was last updated on 3/29/2025 by MarketBeat.com Staff
Buy INCR Stock Free INCR Stock Alerts